Retinoic acid decorated albumin-chitosan nanoparticles for targeted delivery of doxorubicin hydrochloride in hepatocellular carcinoma

Journal of Nanomaterials

Volumn 2013, Issue , 2013, Pages

  Varshosaz, Jaleh ^a   Hassanzadeh, Farshid ^a   Sadeghi, Hojjat ^a   Ghelich Khan, Zahra ^a   Rostami, Mahboobeh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR UPTAKE; DEGREE OF SUBSTITUTION; DOXORUBICIN HYDROCHLORIDE; DRUG-LOADING EFFICIENCY; HEPATOCELLULAR CARCINOMA; RETINOIC ACIDS; TARGETED DELIVERY; TEM MICROGRAPHS;

CHITOSAN; FLUORESCENCE MICROSCOPY; FOURIER TRANSFORM INFRARED SPECTROSCOPY; PARTICLE SIZE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

NANOPARTICLES;

EID: 84877981158     PISSN: 16874110     EISSN: 16874129     Source Type: Journal    
DOI: 10.1155/2013/254127     Document Type: Article

References (49)

1. El-Serag H. B., Hepatocellular carcinoma: an epidemiologic view. Journal of Clinical Gastroenterology 2002 35 supplement 5 S27 S28
2. Llovet J. M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J. F., De Oliveira A. C., Santoro A., Raoul J. L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T. F., Galle P. R., Seitz J. F., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J., Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008 359 4 378 390 2-s2.0-47949116252 10.1056/NEJMoa0708857
3. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002. Ca: A Cancer Journal for Clinicians 2005 55 2 74 108 2-s2.0-14944385553
4. El-Serag H. B., Rudolph K. L., Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 7 2557 2576 2-s2.0-34250020201 10.1053/j.gastro.2007.04.061
5. Rustgi V. K., Epidemiology of hepatocellular carcinoma. Gastroenterology Clinics of North America 1987 16 4 545 551 2-s2.0-0023475719
6. London W. T., Primary hepatocellular carcinoma-etiology, pathogenesis, and prevention. Human Pathology 1981 12 12 1085 1097 2-s2.0-0019805453
7. Lai C. L., Gregory P. B., Wu P. C., Lok A. S. F., Wong K. P., Ng M. M. T., Hepatocellular carcinoma in Chinese males and females. Possible causes for the male predominance. Cancer 1987 66 5 1107 1110 2-s2.0-0023619777
8. Muir C., Waterhouse J., Powell J., Mack T., Whelan S., Cancer Incidence in Five Continents, Volume 5 1987 New York, NY, USA Oxford University Press
9. Nerenstone S. R., Ihde D. C., Friedman M. A., Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treatment Reviews 1988 15 1 1 31 2-s2.0-0023936352
10. Avila M. A., Berasain C., Sangro B., Prieto J., New therapies for hepatocellular carcinoma. Oncogene 2006 25 27 3866 3884 2-s2.0-33745547361 10.1038/sj.onc.1209550
11. 7402 cell line. Cancer Letters 1999 135 1 97 107 2-s2.0-0032416015
12. Llovet J. M., Burroughs A., Bruix J., Hepatocellular carcinoma. The Lancet 2003 362 9399 1907 1917 2-s2.0-0141491273 10.1016/S0140-6736(03)14964-1
13. Jensen P. B., Sorensen B. S., Sehested M., Demant E. J. F., Kjeldsen E., Friche E., Hansen H. H., Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochemical Pharmacology 1993 45 10 2025 2035 2-s2.0-0027194055 10.1016/0006-2952(93)90013-M
14. Shan K., Michael Lincoff A., Young J. B., Anthracycline-induced cardiotoxicity. Annals of Internal Medicine 1996 125 1 47 58 2-s2.0-0030317942
15. Ruoslahti E., Bhatia S. N., Sailor M. J., Targeting of drugs and nanoparticles to tumors. Journal of Cell Biology 2010 188 6 759 768 2-s2.0-77949762340 10.1083/jcb.200910104
16. Harris T. J., von Maltzahn G., Lord M. E., Park J. H., Agrawal A., Min D. H., Sailor M. J., Bhatia S. N., Protease-triggered unveiling of bioactive nanoparticles. Small 2008 4 1307 1312
17. Moghimi S. M., Hunter A. C., Murray J. C., Long-circulating and target-specific nanoparticles: theory to practice. Pharmacological Reviews 2001 53 2 283 318 2-s2.0-0034996764
18. Wagner S., Rothweiler F., Anhorn M. G., Sauer D., Riemann I., Weiss E. C., Katsen-Globa A., Michaelis M., Cinatl J., Schwartz D., Kreuter J., von Briesen H., Langer K., Enhanced drug targeting by attachment of an anti α v integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 2010 31 8 2388 2398 2-s2.0-74449089443 10.1016/j.biomaterials.2009. 11.093
19. Chen J., Wu H., Han D., Xie C., Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Letters 2006 231 2 169 175 2-s2.0-29844446910 10.1016/j.canlet.2005.01.024
20. Liu P., Li Z., Zhu M., Sun Y., Li Y., Wang H., Duan Y., Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. Journal of Materials Science 2010 21 2 551 556 2-s2.0-77951253330 10.1007/s10856-009-3925-8
21. Kim T. H., Park I. K., Nah J. W., Choi Y. J., Cho C. S., Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials 2004 25 17 3783 3792 2-s2.0-1542268858 10.1016/j.biomaterials.2003.10.063
22. Sano K., Takayama T., Murakami K., Saiki I., Makuuchi M., Overexpression of retinoic acid receptor α in hepatocellular carcinoma. Clinical Cancer Research 2003 9 10 I 3679 3683 2-s2.0-0141456447
23. Edeline J., Raoul J. L., Vauleon E., Guillygomac'h A., Boudjema K., Boucher E., Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World Journal of Gastroenterology 2009 15 6 713 716 2-s2.0-65649102210 10.3748/wjg.15.713
24. Sever C. E., Locker J., Expression of retinoic acid α and β receptor genes in liver and hepatocellular carcinoma. Molecular Carcinogenesis 1991 4 2 138 144 2-s2.0-0025756606
25. Schug T. T., Berry D. C., Shaw N. S., Travis S. N., Noy N., Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007 129 4 723 733 2-s2.0-34249087361 10.1016/j.cell.2007.02.050
26. Recchia F., Saggio G., Cesta A., Candeloro G., Di Blasio A., Amiconi G., Lombardo M., Nuzzo A., Lalli A., Alesse E., Necozione S., Rea S., Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer. Cancer Immunology, Immunotherapy 2007 56 5 699 708 2-s2.0-33847389749 10.1007/s00262-006-0224-9
27. Guo J., Xiao B., Lou Y., Yan C., Zhan L., Wang D., Zhao W., Antitumor effects of all-trans-retinoic acid on cultured human pancreatic cancer cells. Journal of Gastroenterology and Hepatology 2006 21 2 443 448 2-s2.0-33645215071 10.1111/j.1440-1746.2006.04180.x
28. Tsimberidou A. M., Tirado-Gomez M., Andreeff M., O'Brien S., Kantarjian H., Keating M., Lopez-Berestein G., Estey E., Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leukemia and Lymphoma 2006 47 6 1062 1068 2-s2.0-33746320763 10.1080/10428190500463932
29. Singh B., Murphy R. F., Ding X. Z., Roginsky A. B., Bell R. H. Jr., Adrian T. E., On the role of transforming growth factor- β in the growth inhibitory effects of retinoic acid in human pancreatic cancer cells. Molecular Cancer 2007 6, article no. 82 2-s2.0-39549116113 10.1186/1476-4598-6-82
30. Altucci L., Gronemeyer H., The promise of retinoids to fight against cancer. Nature Reviews Cancer 2001 1 3 181 193 2-s2.0-0035749803
31. Patel M. P., Patel R. R., Patel J. K., Chitosan mediated targeted drug delivery system: a review. Journal of Pharmacy and Pharmaceutical Sciences 2010 13 4 536 557 2-s2.0-78650342641
32. Hirano S., Seino H., Akiyama Y., Nonaka I., Gebelein C. G., Dunn R. L., Chitosan: a biocompatible material for oral and intravenous administration. Progress in Biomedical Polymers 1990 New York, NY, USA Plenum Press
33. Zheng Y., Cai Z., Song X., Chen Q., Bi Y., Li Y., Hou S., Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies. Journal of Drug Targeting 2009 17 4 294 303 2-s2.0-70349217470 10.1080/10611860902737920
34. Lee K. Y., Kwon I. C., Kim Y. H., Jo W. H., Jeong S. Y., Preparation of chitosan self-aggregates as a gene delivery system. Journal of Controlled Release 1998 51 2-3 213 220 2-s2.0-0032509928 10.1016/S0168-3659(97)00173-9
35. Chen L., Subirade M., Chitosan/ β -lactoglobulin core-shell nanoparticles as nutraceutical carriers. Biomaterials 2005 26 30 6041 6053 2-s2.0-20444397373 10.1016/j.biomaterials.2005.03.011
36. Wang T. W., Xu Q., Wu Y., Zeng A. J., Li M., Gao H., Quaternized chitosan (QCS)/poly (aspartic acid) nanoparticles as a protein drug-delivery system. Carbohydrate Research 2009 344 7 908 914 2-s2.0-65249143846 10.1016/j.carres. 2009.02.018
37. Bayomi M. A., Aqueous preparation and evaluation of albumin-chitosan microspheres containing indomethacin. Drug Development and Industrial Pharmacy 2004 30 4 329 339 2-s2.0-3343016755 10.1081/DDC-120030425
38. Elzoghby A. O., Samy W. M., Elgindy N. A., Albumin-based nanoparticles as potential controlled release drug delivery systems. Journal of Controlled Release 2012 157 2 168 182
39. van Dalen E. C., Michiels E. M., Caron H. N., Kremer L. C., Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database of Systematic Reviews 2010 3 CD005006 2-s2.0-77951248352
40. Fattahi A., Golozar M. A., Varshosaz J., Sadeghi M. H., Fathi M., Preparation and characterization of micelles of oligomeric chitosan linked to all trans retinoic acid. Carbohydrate Polymers 2012 87 1176 1184
41. Qi J., Yao P., He F., Yu C., Huang C., Nanoparticles with dextran/chitosan shell and BSA/chitosan core-doxorubicin loading and delivery. International Journal of Pharmaceutics 2010 393 1-2 176 184 2-s2.0-77956221582
42. Denkbaş E. B., Kiliçay E., Birlikseven C., Öztürk E., Magnetic chitosan microspheres: preparation and characterization. Reactive and Functional Polymers 2002 50 225 232
43. Ge Y. B., Chen D. W., Xie L. P., Zhang R. Q., Optimized preparation of daidzein-loaded chitosan microspheres and in vivo evaluation after intramuscular injection in rats. International Journal of Pharmaceutics 2007 338 1-2 142 151 2-s2.0-34249059753 10.1016/j.ijpharm.2007.01.046
44. Bayomi M. A., Al-Suwayeh S. A., El-Helw A. M., Mesnad A. F., Preparation of casein-chitosan microspheres containing diltiazem hydrochloride by an aqueous coacervation technique. Pharmaceutica Acta Helvetiae 1998 73 4 187 192 2-s2.0-0032403648 10.1016/S0031-6865(98)00020-X
45. Freitas C., Müller R. H., Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN) dispersions. International Journal of Pharmaceutics 1998 168 2 221 229 2-s2.0-0032526787 10.1016/S0378-5173(98)00092-1
46. Sinha V. R., Singla A. K., Wadhawan S., Kaushik R., Kumria R., Bansal K., Dhawan S., Chitosan microspheres as a potential carrier for drugs. International Journal of Pharmaceutics 2004 274 1-2 1 33 2-s2.0-1842452953 10.1016/j.ijpharm.2003.12.026
47. Nishioka Y., kyotani S., Masui H., Okamura M., Miyazaki M., Ok azaki K., Ohnishi S., Yamamoto Y., Ito K., Preparation and release characteristics of cisplatin albumin microspheres containing chitin and treated with chitosan. Chemical and Pharmaceutical Bulletin 1989 37 11 3074 3077 2-s2.0-0024829022
48. Babu G. V. M. M., Prasad C. D. S., Narayan C. P. S., Murthy K. V. R., New system for microencapsulation of diclofenac sodium using gum karaya and chitosan. Saudi Pharmaceutical Journal 2001 9 3-4 169 178 2-s2.0-0035661520
49. Antonyak M. A., Singh U. S., Lee D. A., Boehm J. E., Combs C., Zgola M. M., Page R. L., Cerione R. A., Effects of tissue trans glutaminase on retinoic acid-induced cellular differentiation and protection against a poptosis. The Journal of Biological Chemistry 2001 276 36 33582 33587 2-s2.0-0035823548 10.1074/jbc.M105318200